Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 13/20 | 0.48 |
| ▸ | GUCY1A2 | P33402 | 13/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16906968 | 0.89 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SIRT5 | |
| SCHEMBL16806976 | 0.88 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SIRT5 | |
| SCHEMBL17620505 | 0.86 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SIRT5 | |
| SCHEMBL20284705 | 0.86 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SIRT5 | |
| SCHEMBL16082645 | 0.85 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16081902 | 0.82 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16081875 | 0.79 | GUCY1B2 (0.73) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL20310014 | 0.78 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL23666457 | 0.78 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17620437 | 0.77 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214364-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 4/4885GUCY1A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.